BOC Sciences provides enabling formulation technology support for drug candidates that cannot achieve suitable solubility, dissolution, stability, drug loading, or delivery performance with a conventional formulation. Our scientists connect API characterization, technology selection, prototype preparation, and performance testing within integrated formulation services. The goal is to identify a practical formulation pathway that addresses the molecule's dominant barrier without adding unnecessary formulation complexity.
Enabling formulation technology support is the science-based selection and development of formulation approaches that help a difficult API become usable in a dosage form. It is commonly needed when low aqueous solubility, slow dissolution, strong crystal-lattice energy, high lipophilicity, rapid precipitation, limited permeability, chemical instability, or an excessive excipient requirement restricts development.
A successful program begins by identifying the mechanism behind the performance limitation. BOC Sciences then compares suitable options from its broader solubility improvement and delivery technology portfolio. Candidate systems are assessed against drug loading, physical and chemical stability, dissolution behavior, dosage-form compatibility, material availability, and process feasibility so that the selected technology is supported by comparative data rather than platform preference.
We develop solution-based and colloidal systems that increase apparent solubility while controlling precipitation, dilution effects, and excipient exposure.
BOC Sciences screens molecular hosts that shield hydrophobic regions of an API and increase its apparent aqueous solubility without covalent modification.
Our particle engineering work increases effective surface area and dissolution rate while preserving a crystalline drug form when an amorphous strategy is unnecessary or unsuitable.
We disperse an API within a polymeric carrier to reduce the crystal-lattice barrier, generate supersaturation, and delay drug precipitation during dissolution.
BOC Sciences develops lipid-based systems that maintain a lipophilic API in a solubilized or finely dispersed state before and after aqueous dilution.
We evaluate whether a modified crystalline or amorphous form can improve solubility, dissolution, stability, or processing before a more excipient-intensive formulation is selected.
Share the API structure, available solid-form and solubility data, intended dosage form, target drug loading, material availability, and current performance barrier. BOC Sciences will help define a focused comparison plan instead of starting with a single preferred platform.
BOC Sciences adapts the scope to the compound, available material, current data, dosage-form goal, and decision that the client needs to make. Typical project types include:
| Project Type | Service Scope & Key Outputs |
| Enabling Technology Feasibility | Compound risk mapping, technology shortlisting, microscale prototypes, comparative solubility and dissolution data, stability observations, and a documented recommendation for the next formulation stage. |
| Poor-Solubility Formulation Rescue | Root-cause review of an underperforming formulation followed by targeted comparison of solid dispersion, nanocrystal, complexation, lipid, surfactant, or solid-form options. |
| Supersaturation and Precipitation Control | pH-shift and non-sink testing, precipitation-inhibitor screening, polymer or surfactant selection, and kinetic profiling to extend useful dissolved-drug concentrations after release. |
| High-Loading Formulation Development | Optimization of drug-to-carrier ratio, excipient burden, processability, and dissolution to preserve performance while keeping the final dose size practical. |
| Particulate and Nanocarrier Formulations | Development of suspensions, nanocrystals, liposomes, lipid particles, and ligand-modified carriers with particle size, loading, release, leakage, and colloidal stability assessment. |
| Dosage-Form Integration | Conversion of an enabled intermediate into a compatible liquid, capsule, granule, tablet, or reconstitutable system, including support for oral solid dose development. |
| Route-Specific Technology Selection | Comparison of solubilization, release, carrier, and stability requirements after the intended route of administration and dosage-form constraints have been defined. |
Tell us whether the main problem is solubility, dissolution, precipitation, permeability, instability, low drug loading, particle growth, or poor target-site delivery. Our team will define the minimum experiments needed to compare realistic technology options and produce decision-ready data.
We confirm the target dosage form, administration route, dose range, performance objective, available API quantity, preferred excipients, known incompatibilities, and existing physicochemical or formulation data. The review identifies which questions are already answered and which measurements are necessary before prototype work begins.
BOC Sciences maps the dominant barrier using solubility, ionization, lipophilicity, permeability, crystal form, thermal behavior, dose, and stability information. Technologies are shortlisted according to mechanism and practical fit, while options with unacceptable loading, compatibility, or processing risks are deprioritized.
Small-scale prototypes are prepared across selected technology families and evaluated with tests matched to their mechanisms. Solubility, dissolution, supersaturation, particle size, solid state, drug loading, compatibility, release, and short-term stability data are compared using predefined decision criteria.
The leading formulation is refined around composition, process parameters, drug loading, performance, and stability. Clients receive the agreed prototype, analytical results, comparative data, preparation details, risk observations, and a clear technical rationale for selection or further development.
Strong crystal packing, high melting behavior, low ionization, hydrophobic surface area, or poor wettability can keep an API below the dissolved concentration needed for consistent performance. BOC Sciences separates thermodynamic-solubility limitations from dissolution-rate limitations before selecting a technology. pH adjustment, salt or cocrystal formation, amorphous dispersions, nanocrystals, complexation, and lipid systems are compared according to the compound's real mechanism, dose, stability, and dosage-form constraints.
A formulation may create a high dissolved concentration in the preparation vessel but lose that advantage after dilution or a pH change. This spring-and-parachute problem can produce misleading equilibrium-solubility results and unstable performance. We measure precipitation onset and supersaturation duration under non-sink and pH-shift conditions, then adjust polymer, surfactant, complexing agent, lipid composition, drug loading, and release rate to extend the useful dissolved state.
Some enabling systems improve apparent solubility only at carrier-to-drug ratios that make the final dose impractical. We evaluate performance per unit of excipient rather than selecting the formulation with the highest solubility value alone. Drug loading, dosage-form size, viscosity, dispersibility, processing, and stability are considered together. Alternative polymers, solid forms, nanocrystals, mixed mechanisms, or concentrated lipid systems are explored when a first-choice approach requires excessive carrier levels.
Recrystallization, particle growth, agglomeration, phase separation, capsule incompatibility, leakage, moisture uptake, or chemical degradation can erase the initial benefit of an enabled formulation. BOC Sciences uses stress-oriented analytical comparisons to identify the failure mechanism. Stabilizer level, water activity, antioxidant strategy, buffer environment, solidification method, packaging condition, and process parameters are then refined while dissolution, release, solid form, particle attributes, and assay are monitored together.
Collaborate with BOC Sciences to identify the mechanism limiting your molecule, compare enabling technologies with focused experiments, and advance the strongest prototype with integrated formulation, process, dissolution, solid-state, particle, and stability data.
BOC Sciences does not force every molecule into one enabling platform. Technology selection begins with the API's solubility mechanism, ionization, lipophilicity, crystal form, dose, stability, permeability, and dosage-form objective. This reduces platform bias and makes it possible to compare simpler approaches with advanced systems before additional formulation complexity is accepted.
A staged screening design concentrates API use on experiments that change a decision. Microscale solubility, film, precipitation, phase-behavior, or stabilizer studies are used to remove weak options before larger prototypes are prepared. The resulting dataset compares technologies on several attributes, including loading, dissolution, stability, processing, and dosage-form fit.
Enabled formulations are often metastable or structurally complex, so a single assay cannot explain their behavior. Our formulation scientists coordinate chromatographic, solid-state, thermal, particle, dissolution, release, and stability measurements. This integrated interpretation helps distinguish true formulation improvement from temporary solubilization, analytical interference, incomplete recovery, or hidden physical change.
Formulation performance is evaluated together with the process needed to produce and use the material. Drug loading, solvent removal, thermal exposure, particle isolation, redispersion, capsule compatibility, compression, storage sensitivity, and scale-relevant parameters are considered early. This supports selection of a formulation that is not only promising in a screening vial but also practical for continued development.
Client Needs: A drug development group needed an oral formulation for a high-lattice-energy small molecule with low aqueous solubility and weak oral exposure in exploratory research. The team wanted a solid prototype with improved dissolution and sufficient physical stability for continued formulation work.
Challenges: Micronization improved the initial dissolution rate but did not maintain dissolved-drug concentrations. The API also recrystallized rapidly from supersaturated solutions, while high polymer ratios produced an impractically large formulation and slow powder wetting.
Solution: BOC Sciences measured pH-solubility behavior, solid form, thermal transitions, and supersaturation, then compared three polymers and two drug loads using microscale solvent casting. The leading combinations were spray dried and assessed by XRPD, DSC, non-sink dissolution, assay, and short-term stressed storage. Polymer ratio and drying conditions were refined to maintain an amorphous state while improving release and limiting recrystallization.
Outcome: The selected amorphous dispersion maintained a higher dissolved-drug concentration than the crystalline API, retained its amorphous profile during the agreed observation period, and was successfully incorporated into a capsule prototype for further development.
Client Needs: A formulation team required a nanocarrier for a hydrophobic small-molecule payload that showed poor aqueous stability and weak accumulation in the intended target-cell model. The desired system needed controlled release, stable particle attributes, and ligand-mediated target-cell association.
Challenges: Early liposome prototypes showed payload leakage, particle-size drift, and reduced recovery after storage. Increasing ligand density improved cell association but also increased nonspecific uptake in a receptor-low comparison model.
Solution: We screened phospholipid-to-cholesterol ratio, PEG-lipid content, ligand density, buffer pH, and cryoprotectants across 18 microscale liposome prototypes. Particle size, PDI, zeta potential, encapsulation, leakage, release, and short-term stability guided down-selection. The selected carrier was compared in receptor-positive and receptor-low cell models, and ligand density was adjusted to improve target-cell association without increasing nonspecific uptake.
Outcome: The optimized nanocarrier showed improved colloidal stability, reduced payload leakage, controlled release, and a stronger target-to-comparison cell association profile, providing a practical formulation prototype for continued delivery-system research.
An enabling formulation is specifically designed to overcome a physicochemical or biopharmaceutical barrier that a conventional solution, suspension, tablet, or capsule cannot adequately address. It is often considered when an API has poor aqueous solubility, slow dissolution, rapid precipitation, limited permeability, high crystal-lattice energy, chemical instability, or an impractical excipient requirement. The purpose is not simply to maximize apparent solubility. A useful enabling formulation must balance dissolved-drug concentration, stability, drug loading, dosage-form fit, process feasibility, and consistent performance under relevant dilution or dissolution conditions.
Common approaches include pH adjustment and cosolvents, surfactant or micellar solubilization, cyclodextrin complexation, salts and cocrystals, particle size reduction, nanocrystals, amorphous solid dispersions, and lipid-based self-emulsifying systems. Each solves a different problem. Nanocrystals mainly accelerate dissolution; amorphous dispersions reduce the crystal-lattice barrier and can sustain supersaturation; lipid systems help keep lipophilic APIs solubilized during dispersion; and cyclodextrins provide host–guest complexation. Hybrid approaches may be useful when one method cannot simultaneously meet drug-loading, precipitation-control, stability, and dosage-form requirements. Selection depends on compound ionization, lipophilicity, dose, stability, and final dosage-form needs.
The selection should begin with the API rather than a preferred technology. Important inputs include the pH-solubility profile, pKa, logP or logD, permeability, melting and glass-transition behavior, crystal form, dose, chemical stability, and available material. Formulators then identify whether the limiting mechanism is thermodynamic solubility, dissolution rate, precipitation, permeability, or instability. Suitable technologies are compared at small scale using criteria such as drug loading, non-sink dissolution, supersaturation duration, particle or solid-state stability, excipient burden, process feasibility, and compatibility with the intended dosage form. This comparative approach reduces platform bias and prevents an improvement in one property from creating a larger downstream problem.
To begin an enabling formulation project, clients should provide the API structure, salt or solid form, intended dosage form and administration route, approximate dose range, available material quantity, and any excipient restrictions. Existing solubility, pKa, logP or logD, permeability, thermal, crystallinity, hygroscopicity, degradation, dissolution, particle-size, and prior formulation data are also valuable. BOC Sciences reviews the information to identify critical gaps and proposes only the measurements needed for technology selection. If limited data are available, the project can start with a focused developability assessment before prototype screening.
Yes. BOC Sciences can use a staged, material-sparing workflow to compare several realistic technology families without immediately preparing large prototypes. Microscale solubility, phase-behavior, film, precipitation, stabilizer, or excipient screens are used to remove weak options first. Promising systems can then progress to small prototypes for dissolution, solid-state, particle, loading, release, and stability comparisons. The exact design depends on the API and available quantity, so no universal sample requirement is appropriate. Clients receive comparative data, a technical rationale for down-selection, and clearly identified risks for the next formulation stage.
BOC Sciences compared several realistic formulation routes instead of moving directly into one platform. Their explanation of how solubility, crystallinity, drug loading, and precipitation affected the decision made it much easier for our team to select the next development step.
— A Formulation Development Scientist, United States
The recommended formulation addressed the real limitation of our compound without creating an excessive excipient burden. The team considered the intended dosage form, available API, processing constraints, and stability risks, so the proposed strategy felt specific to our molecule rather than copied from a standard platform.
— A Drug Product Project Leader, Germany
The material-sparing screen gave us comparative data across multiple formulation options before larger batches were prepared. Clear stopping criteria and regular updates kept the project moving efficiently, and we were able to focus resources on the strongest prototype rather than repeat serial trial-and-error studies.
— A Drug Development Manager, United Kingdom
The final report connected composition, processing, solid-state behavior, dissolution, particle attributes, and stability observations into one clear technical conclusion. The scientists also explained the remaining risks and which experiments would provide the most value during the next formulation stage.
— A Senior Research Scientist, Switzerland
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
